Drug profile · INN
cipaglucosidase alfa-atga
POMBILITI
cipaglucosidase alfa-atga (POMBILITI) is a glycogen hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Drug details — cipaglucosidase alfa-atga
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
cipaglucosidase alfa-atga (POMBILITI) is a glycogen hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Glycogen hydrolytic enzyme
Primary target: Glycogen
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cipaglucosidase alfa-atga?
cipaglucosidase alfa-atga (POMBILITI) is a glycogen hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for cipaglucosidase alfa-atga?
POMBILITI is a marketed brand name for cipaglucosidase alfa-atga. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cipaglucosidase alfa-atga?
cipaglucosidase alfa-atga has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.